Risk, Causality and Management of Severe Allergic Reactions of RNA Messenger SARS-CoV-2 Vaccine: A Mini Review

Dwitya Elvira1, Raveinal1

1 Allergy Immunology Subdivision, Department of Internal Medicine, Faculty of Medicine, Andalas University/ Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:
Anaphylaxis
Covid-19
mRNA vaccine
Polyethylene glycol
Severe allergy reaction

*Corresponding author:
Dwitya Elvira

E-mail address:
dwitya.elvira@yahoo.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v6i4.475

1. Introduction

The Indonesian Food and Drug Monitoring Agency (BPOM) has just given Emergency Use of Authorization (EUA) to two messenger RNA (mRNA) vaccines, namely BNT162b2 mRNA and mRNA-1273 vaccines as SARS-CoV-2 vaccines in July 2021.1,2 Both vaccines had previously been approved for emergency use in United Kingdom, Bahrain, Canada, Mexico, United States, Singapore, Oman, Saudi Arabia, Kuwait, European Union for BNT162b2 vaccine and in United States and Canada for mRNA-1273 vaccine.3

The mRNA-1273 (Moderna) vaccine is currently planned to be used in approximately 1.5 million health workers as the third dose of vaccine to provide immunity to existing viral mutations, one of which is the delta variant, which was also approved by Indonesian Technician Advisory Group of Immunization (ITAGI) and Health Ministry of Indonesia.4

Reports of clinical trials conducted on both vaccines, the adverse events that occur are low risk, but after mass vaccination, it was reported that there was a severe allergic reaction in the form of anaphylaxis.
in 2 health workers and CDC reported several severe allergy events that were suspected to be related to the vaccine.\textsuperscript{5} This literature review was aimed to explore the risk, causality or the most likely cause of allergies from the vaccine as well as screening and treatment if an unexpected reaction occurs from the vaccine.

**Risk of allergy reactions**

The current COVID-19 vaccination is one of the hopes to eliminate the pandemic quickly, so that more than 200 vaccines from various platforms have been developed, such as inactivated vaccines, messenger RNA (mRNA), viral vector vaccines, protein sub-unit vaccines and various other vaccines platforms.\textsuperscript{6} Recently, Indonesia through BPOM has given approval for the use of the SARS-CoV-2 vaccine with messenger RNA (mRNA) platform, namely the BNT162b2 vaccine produced by Pfizer and BioNTech and mRNA-1273 produced by Moderna in July 2021. The use of this vaccine previously been used in Europe and Asia countries.\textsuperscript{3,4}

The Ministry of Health of the Republic of Indonesia has determined the use of the Moderna mRNA vaccine to be used as a third dose of vaccine for health workers considering the importance of additional vaccination due to new variants that have emerged with the ability to spread faster and high virulence levels.\textsuperscript{4}

Allergic reactions to vaccines, including anaphylaxis, are a rare adverse event reaction (AEFI), which is estimated to occur around 1-10 per 1 million doses of injected vaccine and is usually caused by the presence of excipients, adjuvants and or other components contained in the vaccine itself.\textsuperscript{7} Reports in Europe and America regarding the use of mRNA vaccines show that there is a risk of anaphylactic reactions with 2 cases of anaphylaxis in the UK and 6 cases in the United States after mass vaccination with Pfizer vaccine. The same report in January 2021 also showed that there were 108 cases of severe allergy reaction with 10 cases being anaphylactic reactions after 4,041,396 Moderna vaccinations were injected. Collaborative data showed that there were 21 anaphylaxis events with details of 18 cases appearing immediately after the vaccine was injected (the first 30 minutes), 4 cases requiring hospitalization and 17 cases being admitted to the emergency room.\textsuperscript{8} No deaths were reported as a result of this anaphylactic event. The median time to anaphylaxis was 7.5 minutes (1-45 minutes) from the start of the vaccine injection. The report also shown that anaphylactic reactions were more common in women than men (100% for vaccine mRNA-1273 and 90% for vaccine BNT162b2) for reasons that are still unclear. As many as 81% of patients with anaphylaxis reported having a history of allergies to food, contrast drugs and insect bites, while 41% of patients (7 of 14 people) had a history of previous anaphylaxis including reactions to vaccines.\textsuperscript{9,10,11}

**mRNA vaccines and ingredients**

The development of mRNA vaccines has started since the development of vaccines for Ebola, Zika, and rabies virus infections and is currently used as one of the COVID-19 vaccine platforms. The mRNA vaccine is a vaccine developed with recombinant genetic technology utilizing genetic material in the SARS-CoV-2 virus known as spike protein which is able to trigger an immune reaction against COVID-19.\textsuperscript{12}

The content of the vaccine is shown in Fig. 1 where each vaccine consists of an active component and an excipient. The active component is mRNA that encodes the spike protein that causes SARS-CoV-2 infection and when injected directly without excipient components it will stimulate the mRNA to be absorbed by mononuclear phagocytic cells and will be rapidly degraded by ribonucleases making it difficult to penetrate to the cells. The excipient component is needed as a protective/shield mRNA which is usually in the form of lipid base nanoparticles (LNP). The cation lipid will coat the polyanionic mRNA; cholesterol will act as a stabilizer of the nanoparticle lipid bilayer. Meanwhile, modified PEG (polyethylene glycol) act as a hydration layer which increases the liquid solubility of LNP. This excipient component able to stimulate activation of antigen presenting cells (APC), resulting in upregulation of molecules essential for antigen presentation, such as MHC class II (antigen-specific signal-1) and B7-1/2 and the production of pro-
inflammatory cytokines (nonspecific signal 2). These innate immune events allow the administered antigen to be processed and presented to the adaptive immune system more effectively, resulting in the augmented activation and greater clonal expansion of T cells.\textsuperscript{13,14,15,16}

**Possible causality of allergic reactions**

The suspected cause of allergic and anaphylactic reactions is the excipient component, name as polyethylene glycol (PEG). PEG, also known as macrogol, is a polyether component that is commonly used as an additive in cosmetic, pharmaceutical and food industries. The use of PEG in mRNA vaccines is intended to maintain stability and protection and can increase the immune response to the vaccine. PEG has a molecular weight of 200 – 10,000,000 g/mol. Allergic reactions have been reported to be associated with the use of PEG in drugs and cosmetics, so that PEG is thought to potential to be an allergenic component in vaccines.\textsuperscript{17}

The mRNA vaccine also contains polysorbate 80 which has a molecular weight of 1,310 g/mol so with this low molecular weight it is less likely to be caused by an allergy reaction. Polysorbate80 has been used in previous vaccines such as influenza, hepatitis, so the use of PEG which has a similar molecular structure \(((\text{CH}_2-\text{CHO})_n\)) allows cross-reactivity, although it rarely occurs.\textsuperscript{18}

The exact mechanism of allergic reactions due to PEG is still unclear. Patients with a history of PEG anaphylaxis show high levels of IgE antibodies to PEG. The binding of IgE with PEG allergens to form IgE-FcR1 complexes in mast cells or basophils stimulates the release of histamine, prostaglandins and proteases that trigger an anaphylactic reaction. In general, clinical symptoms of anaphylaxis appear within minutes to an hour after exposure to the allergen, or antigens in vaccines. The results of in vitro studies also show that PEG can trigger complement activation thereby activating the CARPA condition, but these results are still inconclusive in human subjects.\textsuperscript{19}

**Screening and management of severe allergy**

COVID-19 vaccination is aimed to increasing herd immunity which can be achieved if vaccination coverage reaches >60% of the total population. With the possibility of mild to severe allergic reactions including anaphylaxis after vaccination, it is necessary to screen and evaluate the history of allergies in people who will be vaccinated. History of drug allergy, food and manifestations that appear such as urticaria, rash, angioedema, sensation of throat swelling, shortness of breath or anaphylactic shock should be asked at the beginning of the examination. Patients with a history of
Allergies are not contraindicated in mass vaccination against COVID-19, but preparation from the outset in recognizing and treating anaphylaxis is necessary, especially within first 15 to 30 minutes after vaccination. Two things that are important for the safety of vaccination are (i) patients with a history of anaphylaxis or severe allergies should be observed 30 minutes after vaccination, (ii) individuals with a history of vaccine allergy should be screened for allergies either by skin prick test or intradermal test to determine the cause of the allergy.\(^{20,21}\)

Skin prick test or intradermal test can be done using PEG material or vaccines containing polysorbate 80 (Hepatitis or Twinrix). Skin prick test may start with dilution of PEG and polysorbate 1:100; 1:10 dan 1:1 respectively every 30 minute with histamin 1:1 as positive control and gliserin 1:1 as negative control. Intradermal testing using depo medrol (metilprednisolon asetat) 40 mg/ml and triamcinolon acetonide 40 mg/ml with dilution every 30 minutes, 1:100 dan 1:10 respectively and continue with observation for one hour. A number of tests can be performed on people who are suspected to have a previous history of allergies or are known to be allergic to ingredients containing PEG.\(^{22}\) In addition, a basophil activation test and an oral provocation test can also be performed.

Preparations that are important in the management of severe allergic reactions/anaphylaxis are injections of IM epinephrine with adequate doses (can be repeated if the condition has not been treated) by keeping the patient in a resting position, oxygen (facial mask oxygen), 0.9% IV NaCl fluids, medication antihistamines and corticosteroids and close monitoring is needed in people who have a history of previous allergies. Provision of emergency drugs for the management of anaphylaxis is needed in health facilities with experienced staff in carrying out vaccination programs to avoid the possibility of this severe allergic reaction occurring.

**2. Conclusion**

The risk of severe allergy/anaphylaxis is a rare reaction after vaccination. This type of reaction is usually rapid within 15-30 minutes after the vaccine so close monitoring is needed in people who have a history of previous allergies. Provision of emergency drugs for the management of anaphylaxis is needed in health facilities with experienced staff in carrying out vaccination programs to avoid the possibility of this severe allergic reaction occurring.

**3. References**


